Electra Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $300.0Mattributed |
|---|---|
| Latest round | series-c, $183.0M, 2025-10-01attributed |
| Founded | 2018 |
| Headquarters | South San Francisco CA |
| Industry | bio |
| Stage | series-b+ |
| Website | electratherapeutics.com |
Electra Therapeutics develops first-in-class monoclonal antibodies targeting signal regulatory proteins (SIRPs) on immune cells, led by ELA026 for secondary hemophagocytic lymphohistiocytosis. It treats sHLH (100% Phase 1b 8-week survival) and is expanding into hematologic cancers. Electra's SIRP antibodies spare the CD47/SIRPα checkpoint.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-c | $183.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $183.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $300.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | electratherapeutics.com, read 2026-05-02 |
| Description | self-reported | electratherapeutics.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.